Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Jan 19, 2023
Date Accepted: Oct 17, 2023
Date Submitted to PubMed: Oct 17, 2023
CD4/CD8 Ratio Recovered As a Predictor of Decrease Liver Damage in HIV-Infected Adults: A 16-Year Observational Cohort Study
ABSTRACT
Background:
Background:
Since more HIV-infected people are living longer, it is crucial to monitor the number of non-AIDS-related events, especially liver diseases. Liver-related deaths in HIV-infected patients occur more often in comparison with the general population. The CD4/CD8 ratio is considered an emerging biomarker for non-AIDS-related events. However, the current research was rarely designed to investigate the connection between the CD4/CD8 ratio and certain types of non-AIDS-related events, particularly liver damage.
Objective:
Objective:
The aim of this study was to determine whether the CD4/CD8 ratio was associated with the development of liver damage in a large cohort of HIV-infected patients receiving antiretroviral treatment (ART) and to evaluate the efficacy of three antiretroviral drugs in normalizing the CD4/CD8 ratio and lowering the incidence of liver damage among this population.
Methods:
Methods:
An observational cohort study was conducted among HIV-infected adults receiving ART from 2004 to 2020 in Guangxi, China. Propensity score matching, multivariable Cox proportional hazard and Fine-Gray competing risk regression models were constructed to determine the relationship of CD4/CD8 ratio normalization with liver damage.
Results:
Results:
The incidence of liver damage was 20.12% among 2,440 eligible individuals during a median of four person-years of follow-up. Patients whose CD4/CD8 ratio did not normalize to 1.0 had a higher liver damage incidence than patients whose CD4/CD8 ratio normalized (adjusted HR = 7.90, 95% CI 4.39–14.21, P < 0.001; sub-distribution HR = 6.80, 95% CI 3.83–12.11, P < 0.001), similar to the PSM analysis (aHR = 6.94, 95% CI 3.41–14.12, P < 0.001; sHR = 5.67, 95% CI 2.74–11.73, P< 0.001). The Efavirdine-based regimen required the least time to normalize the CD4/CD8 ratio (71 months IQR 49–88) and had a lower prevalence of liver damage (4.18 /100 person-years).
Conclusions:
Conclusions:
Normalization of the CD4/CD8 ratio was associated with a decreased risk of liver damage in HIV-infected patients receiving ART, providing further evidence that the CD4/CD8 ratio might be utilized to identify people at risk of non-AIDS-related diseases. Efavirdine-based regimen was a recommended option for normalizing the CD4/CD8 ratio and reducing the risk of liver damage.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.